MedPal AI (MPAL) Trading update summary
Event summary combining transcript, slides, and related documents.
Trading update summary
4 Nov, 2026Trading performance
New Health revenue was £3.63m in October, up 33% from £2.73m in September, across 29,450 orders.
Group revenue was ~£4.1m, up from ~£3.2m in September; annualised October run rate was over £49m, a pro forma calculation and not a forecast.
NHS prescriptions and eMARX subscriptions contributed ~£0.5m of October revenue.
Repeat orders and customers
New Health repeat order revenue more than doubled to £1.34m in October, 37% of New Health revenue, versus £0.63m and 23% in September; August revenue was ~£0.1m.
Repeat orders were received from 46% of customers whose 28-day reorder fell due in October; repeat orders had ~23% higher average order value than first orders and no acquisition cost.
Repeat orders and recurring subscriptions generated ~£1.8m, 45% of Group October revenue, up from ~33% in September.
New Health served almost 20,000 new customers in October and over 53,000 since marketing began in July; this equated to ~2.7% of the cited estimate of 2m UK GLP-1 weight-management users.
Operations and technology
New Health customer services and prescribing moved to seven days a week; pharmacy dispensing operates six days a week, with Sunday delivery added.
Juno sent 91% of New Health WhatsApp replies in October, with 85% of conversations handled without human involvement.
Latest events from MedPal AI
- Record daily orders, ~£6.36m in cash, debtors and stock, and no equity raise planned.MPAL
Trading update - Annualised recurring revenue exceeded £8.6 million in July, driven by record growth across all streams.MPAL
Trading update - First-half revenue reached £1.6m with pharmacy scale-up; strong growth and profitability targeted.MPAL
H1 2026 - Loss before tax of £4m, rapid post-year-end revenue growth, and material going concern uncertainty.MPAL
H2 2025 - AI-powered pharmacy operations saw rapid growth and secured flexible funding for further expansion.MPAL
Trading update - Prescription volumes rose 16% as new oral GLP-1 approval expands the weight loss market.MPAL
Trading update